MCID: CRD137
MIFTS: 45

Cardiogenic Shock

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Cardiogenic Shock

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 55 59
Shock, Cardiogenic 69
Shock Cardiogenic 51

Characteristics:

Orphanet epidemiological data:

55
cardiogenic shock
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

Orphanet 55 ORPHA97292
UMLS via Orphanet 70 C0036980
ICD10 via Orphanet 33 R57.0
ICD10 32 R57.0
UMLS 69 C0036980

Summaries for Cardiogenic Shock

PubMed Health : 59
About cardiogenic shock: Cardiogenic (kar-dee-oh-JE-nik) shock is a condition in which a suddenly weakened heart isn't able to pump enough blood to meet the body's needs. The condition is a medical emergency and is fatal if not treated right away.The most common cause of cardiogenic shock is damage to the heart muscle from a severe heart attack. However, not everyone who has a heart attack has cardiogenic shock. In fact, on average, only about 7 percent of people who have heart attacks develop the condition.If cardiogenic shock does occur, it's very dangerous. When people die from heart attacks in hospitals, cardiogenic shock is the most common cause of death.

MalaCards based summary : Cardiogenic Shock, also known as shock, cardiogenic, is related to myocardial infarction and myocarditis, and has symptoms including shock without mention of trauma and syncope. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Selenium Micronutrient Network and IL-6 signaling pathway. The drugs Dobutamine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and bone.

Wikipedia : 72 Cardiogenic shock is a life-threatening medical condition resulting from an inadequate circulation of... more...

Related Diseases for Cardiogenic Shock

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 myocardial infarction 30.6 CRP IL6 NPPB PIK3C2A PLAT
2 myocarditis 30.5 IL6 NPPB
3 atrioventricular block 30.3 NPPB PIK3C2A
4 acute myocardial infarction 29.8 CRP NPPB PIK3C2A PLAT
5 infective endocarditis 29.7 CRP IL6
6 peripheral artery disease 29.7 CRP IL6
7 endocarditis 29.6 CRP IL6 PIK3C2A
8 anterolateral myocardial infarction 29.6 NPPB PLAT
9 takayasu arteritis 29.6 CRP IL6
10 inferior myocardial infarction 29.6 NPPB PIK3C2A PLAT
11 pneumonia 29.4 CRP IL6 PIK3C2A
12 pericarditis 29.3 CRP IL6 NPPB
13 pulmonary edema 29.2 CRP NPPB PIK3C2A
14 kawasaki disease 29.2 CRP IL6 NPPB
15 pulmonary embolism 29.1 CRP NPPB PLAT
16 diabetes mellitus 29.1 CRP IL6 PIK3C2A
17 dilated cardiomyopathy 29.0 CRP IL6 NPPB
18 pulmonary hypertension 29.0 IL6 NPPB PLAT
19 arteries, anomalies of 28.9 CRP IL6 NPPB PLAT
20 coronary artery anomaly 28.3 CRP IL6 NPPB PIK3C2A PLAT
21 cardiac tamponade 11.4
22 ogden syndrome 11.1
23 cardiac arrest 10.3
24 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 10.3
25 thrombosis 10.3
26 toxic myocarditis 10.2 NPPB PIK3C2A
27 hand, foot and mouth disease 10.2 IL6 NPPB
28 leukomalacia 10.2 IL6 NPPB
29 blood group, i system 10.2
30 pheochromocytoma 10.2
31 vibrio vulnificus infection 10.2 IL6 PIK3C2A
32 crimean-congo hemorrhagic fever 10.2 IL6 PIK3C2A
33 chronic thromboembolic pulmonary hypertension 10.2 CRP NPPB
34 extrinsic cardiomyopathy 10.2 IL6 PIK3C2A
35 cold agglutinin disease 10.1 CRP IL6
36 diabetic foot ulcers 10.1 CRP IL6
37 cryopyrin-associated periodic syndrome 10.1 CRP IL6
38 neutrophilia, hereditary 10.1 CRP IL6
39 acute cholangitis 10.1 CRP IL6
40 uremic pruritus 10.1 CRP IL6
41 spinal disease 10.1 CRP IL6
42 castleman disease 10.1 CRP IL6
43 heart conduction disease 10.1 CRP NPPB
44 viral pneumonia 10.1 CRP IL6
45 cecal disease 10.1 CRP IL6
46 relapsing polychondritis 10.1 CRP IL6
47 central nervous system vasculitis 10.1 CRP IL6
48 subacute thyroiditis 10.1 CRP IL6
49 intussusception 10.1 CRP IL6
50 louse-borne relapsing fever 10.1 CRP IL6

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Cardiac Arrest Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Intermediate Coronary Syndrome Ischemic Heart Disease
Kidney Disease Mitral Valve Disease
Peripheral Vascular Disease Respiratory Failure
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:



Diseases related to Cardiogenic Shock

Symptoms & Phenotypes for Cardiogenic Shock

UMLS symptoms related to Cardiogenic Shock:


shock without mention of trauma, syncope

Drugs & Therapeutics for Cardiogenic Shock

PubMedHealth treatment related to Cardiogenic Shock: 59

Cardiogenic shock is life threatening and requires emergency medical treatment. The condition usually is diagnosed after a person has been admitted to a hospital for a heart attack. If the person isn't already in a hospital, emergency treatment can start as soon as medical personnel arrive.The first goal of emergency treatment for cardiogenic shock is to improve the flow of blood and oxygen to the body’s organs.Sometimes both the shock and its cause are treated at the same time. For example, doctors may quickly open a blocked blood vessel that's damaging the heart. Often, this can get the patient out of shock with little or no additional treatment.

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dobutamine Approved Phase 4,Phase 3,Phase 2 34368-04-2 36811
2
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
3
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
4 Racepinephrine Approved Phase 4,Phase 2 329-65-7
5
Abciximab Approved Phase 4 143653-53-6
6
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
9
Everolimus Approved Phase 4 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
12
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
13
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 46507594 772
14
Tenecteplase Approved Phase 4,Phase 2,Phase 3 191588-94-0
15
Milrinone Approved Phase 4 78415-72-2 4197
16
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
17 Simendan Investigational Phase 4,Phase 2,Phase 3 131741-08-7
18 Adrenergic Agents Phase 4,Phase 3,Phase 2
19 Adrenergic Agonists Phase 4,Phase 3,Phase 2
20 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
21 Autonomic Agents Phase 4,Phase 3,Phase 2
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
24 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
25 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
26 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3
27 Protective Agents Phase 4,Phase 3,Phase 2
28 Vasodilator Agents Phase 4,Phase 2,Phase 3
29 Analgesics Phase 4
30 Anesthetics Phase 4
31 Central Nervous System Depressants Phase 4,Phase 2
32 Hypnotics and Sedatives Phase 4
33 Anti-Bacterial Agents Phase 4
34 Anti-Infective Agents Phase 4,Phase 2
35 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
36 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
37 Bronchodilator Agents Phase 4,Phase 3,Phase 2
38 Epinephryl borate Phase 4,Phase 2
39 Mydriatics Phase 4,Phase 2
40 Respiratory System Agents Phase 4,Phase 3,Phase 2
41 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
42 Antibodies Phase 4
43 Antibodies, Monoclonal Phase 4
44 Anticoagulants Phase 4,Phase 3,Phase 2
45 Immunoglobulin Fab Fragments Phase 4
46 Immunoglobulins Phase 4
47 Adrenergic alpha-2 Receptor Agonists Phase 4
48 Analgesics, Non-Narcotic Phase 4
49 Anesthetics, Local Phase 4
50 Antibiotics, Antitubercular Phase 4

Interventional clinical trials:

(show top 50) (show all 114)

# Name Status NCT ID Phase Drugs
1 Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
2 Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock Completed NCT01927549 Phase 4
3 Intraaortic Balloon Pump in Cardiogenic Shock II Completed NCT00491036 Phase 4
4 Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock Completed NCT00420030 Phase 4 Abciximab
5 Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK) Completed NCT00417378 Phase 4
6 Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
7 Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. Completed NCT00324766 Phase 4 levosimendan;placebo,
8 Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial) Completed NCT02630290 Phase 4 Ropivacaine;Ropivacaine + Dexmedetomidine
9 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
10 To Investigate the Role of Upstream High Dose Statin in STEMI Completed NCT01050348 Phase 4 Atorvastatin calcium;Inactive Placebo
11 Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Completed NCT01634425 Phase 4
12 Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial. Completed NCT01311700 Phase 4 Injectable (i.v.) metoprolol tartrate (up to 15 mg).
13 Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Recruiting NCT02544594 Phase 4
14 ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock Recruiting NCT02301819 Phase 4
15 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
16 Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive Recruiting NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
17 Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock Not yet recruiting NCT03437369 Phase 4 Ivabradine Oral Tablet
18 Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine Not yet recruiting NCT03387605 Phase 4 Ivabradine;Placebo
19 Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock Terminated NCT00314847 Phase 4
20 A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI) Terminated NCT00168792 Phase 4 Tenecteplase
21 Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery Unknown status NCT02361801 Phase 3 Liberal dobutamine protocol;Restrictive dobutamine protocol
22 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
23 Levosimendan Versus Dobutamine in Shock Patients Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
24 Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients Unknown status NCT02432976 Phase 2, Phase 3 Exenatide;Insulin
25 Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction (NSTEMI) Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention (PCI) Unknown status NCT01478984 Phase 3
26 Best Bypass Surgery (BBS) Trial Unknown status NCT00120991 Phase 3
27 Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. Completed NCT00000552 Phase 3 thrombolytic therapy
28 Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI) Completed NCT00251823 Phase 3 Eptifibatide facilitated PCI
29 The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study Completed NCT00882635 Phase 3 enoxaparin;Unfractionated heparin
30 Dopamine and Norepinephrine in Shock Patients Completed NCT00314704 Phase 3 dopamine versus norepinephrine
31 Which Therapy for Acute Heart Attacks? (The WEST Study) Completed NCT00121446 Phase 2, Phase 3 tenecteplase;enoxaparin;clopidogrel
32 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed NCT00623623 Phase 3 enoxaparin;tenecteplase;clopidogrel
33 REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) Completed NCT00640991 Phase 3 glulisine insulin, glargine insulin
34 Danish Cardiogenic Shock Trial Recruiting NCT01633502 Phase 3
35 Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock Recruiting NCT02633358 Phase 2, Phase 3
36 Bromocriptine in the Treatment of Peripartum Cardiomyopathy Recruiting NCT02590601 Phase 3 Bromocriptine
37 Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock Not yet recruiting NCT03340779 Phase 3 Norepinephrine
38 Effect of External Counter Pulsation on Ischemic Stroke Not yet recruiting NCT03075137 Phase 3
39 Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction Not yet recruiting NCT02905760 Phase 3 Furosemide;Placebo filling;Placebo furosemide;Vascular filling
40 A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack Terminated NCT00112281 Phase 3 Tilarginine Acetate Injection intravenous infusion
41 Clot Dissolving Treatment for Blood Clots in the Lungs Terminated NCT00680628 Phase 3 Tenecteplase + Enoxaparin;0.9% Saline + Enoxaparin
42 Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine Unknown status NCT01186783 Phase 2 ivabradine
43 Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation Completed NCT00604331 Phase 2 Pyruvate
44 Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia Completed NCT02841241 Phase 2 Esmolol
45 Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Recruiting NCT02591771 Phase 2 adrenaline
46 Exenatide for Myocardial Protection During Reperfusion Study Recruiting NCT01938235 Phase 2 Exenatide;Placebo
47 HEROIC (Heparin Requirement in Counterpulsation) Terminated NCT00445211 Phase 2 Heparin
48 The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty Terminated NCT00640094 Phase 2 melatonin
49 Catheter Thrombectomy in Patients With Massive Pulmonary Embolism Terminated NCT00314002 Phase 1, Phase 2
50 The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients Terminated NCT00782652 Phase 2 inhaled nitric oxide;nitrogen gas

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Cardiogenic Shock

Anatomical Context for Cardiogenic Shock

MalaCards organs/tissues related to Cardiogenic Shock:

38
Heart, Lung, Bone, Liver, Skeletal Muscle, Kidney, Endothelial

Publications for Cardiogenic Shock

Articles related to Cardiogenic Shock:

(show top 50) (show all 718)
# Title Authors Year
1
Mechanical support in cardiogenic shock complicating acute coronary syndrome: ready for prime time? ( 29345584 )
2018
2
Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left ventricular failure. ( 29405734 )
2018
3
National Trends, Predictors of Use, and In-Hospital Outcomes in the Mechanical Circulatory Support for Cardiogenic Shock. ( 29400657 )
2018
4
Cardiogenic shock: the next frontier in acute cardiovascular care! ( 29412021 )
2018
5
Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial. ( 29423774 )
2018
6
Is index procedure complete revascularization really essential for ST-elevation myocardial infarction with cardiogenic shock? ( 29430782 )
2018
7
Optimal course of treatment in acute cardiogenic shock complicating myocardial infarction. ( 29310471 )
2018
8
Predictors of cardiogenic shock in cardiac surgery patients receiving intra-aortic balloon pumps. ( 29395233 )
2018
9
Extracorporeal life support in cardiogenic shock: indications and management in current practice. ( 29349674 )
2018
10
Weaning adult patients with cardiogenic shock on veno-arterial extracorporeal membrane oxygenation by pump-controlled retrograde trial off. ( 29409389 )
2018
11
Blood lactate is a predictor of short-term mortality in patients with myocardial infarction complicated by heart failure but without cardiogenic shock. ( 29347907 )
2018
12
Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock. ( 29424484 )
2018
13
Predictive Value of Procalcitonin for Infection and Survival in Adult Cardiogenic Shock Patients Treated with Extracorporeal Membrane Oxygenation. ( 29399566 )
2018
14
A Right Insight in Cardiogenic Shock to Get It Right. ( 29374583 )
2018
15
Early Electroencephalography Findings in Cardiogenic Shock Patients Treated by Venoarterial Extracorporeal Membrane Oxygenation. ( 29389771 )
2018
16
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. ( 29376560 )
2018
17
Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. ( 29400656 )
2018
18
Plasma Concentration of Biomarkers Reflecting Endothelial Cell- and Glycocalyx Damage are Increased in Patients with Suspected St-Elevation Myocardial Infarction Complicated by Cardiogenic Shock. ( 29438221 )
2018
19
The Use of ECMO for the Treatment of Refractory Cardiac Arrest or Postarrest Cardiogenic Shock Following In-Hospital Cardiac Arrest: A 10-Year Experience. ( 29303029 )
2018
20
Transvenous Inoue balloon aortic valvuloplasty with intra-aortic balloon pump in treating cardiogenic shock due to critical calcific aortic stenosis. ( 28044253 )
2017
21
Transcatheter Aortic Valve Replacement With TandemHeart Support in a Patient With Cardiogenic Shock. ( 29428357 )
2017
22
Integrating invasive hemodynamic parameters into risk stratification of acute myocardial infarction and cardiogenic shock. ( 28891162 )
2017
23
Acute Idiopathic Gastric Distension Causing Atrioventricular Block and Cardiogenic Shock. ( 28602457 )
2017
24
Bridge to transplant or recovery in cardiogenic shock in a developing country. ( 28084085 )
2017
25
Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis. ( 28911298 )
2017
26
In-hospital outcomes of acute myocardial infarction with cardiogenic shock caused by right coronary artery occlusion vs. left coronary artery occlusion. ( 28918455 )
2017
27
Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. ( 28806755 )
2017
28
Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. ( 28043661 )
2017
29
Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): theA need for a better definition of refractory cardiogenic shock. ( 28925084 )
2017
30
Extracorporeal membrane oxygenation for cardiogenic shock due to alcoholic cardiomyopathy: a long-term follow-up of 4 cases. ( 29281011 )
2017
31
Trends in the Incidence and In-Hospital Outcomes of Cardiogenic Shock Complicating Thyroid Storm. ( 28864374 )
2017
32
A dual therapy of off-pump temporary left ventricular extracorporeal device and amniotic stem cell for cardiogenic shock. ( 28882138 )
2017
33
Utilization of the Impella for hemodynamic support during percutaneous intervention and cardiogenic shock: an insight. ( 28862481 )
2017
34
Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients. ( 28822659 )
2017
35
Acute Heart Failure Exacerbation with Cardiogenic Shock and Elevated Systemic Vascular Resistance Treated with a Combination of Nicardipine and Dobutamine Therapy. ( 28845316 )
2017
36
Successful Use of Extracorporeal Membrane Oxygenation for the Treatment of Cardiogenic Shock due to Scorpion Envenomation. ( 28536661 )
2017
37
Triheptanoin: A Rescue Therapy for Cardiogenic Shock in Carnitine-acylcarnitine Translocase Deficiency. ( 28689308 )
2017
38
Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture. ( 28017176 )
2017
39
De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. ( 28948707 )
2017
40
A Case of Cardiogenic Shock Secondary to Complement-Mediated Myopericarditis From InfluenzaA BA Infection. ( 28844428 )
2017
41
Predictive value of SYNTAX score II for clinical outcomes in cardiogenic shock underwent primary percutaneous coronary intervention; a pilot study. ( 28889354 )
2017
42
Prognostic Value of Relative Adrenal Insufficiency During Cardiogenic Shock: A Prospective Cohort Study With Long-Term Follow-Up. ( 27984534 )
2017
43
The prognostic value of MR-proadrenomedullin in patients with acute coronary syndrome complicated by cardiogenic shock. ( 27788594 )
2017
44
Left ventricular perforation after ImpellaAr placement in a patient with cardiogenic shock. ( 28944588 )
2017
45
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. ( 28923988 )
2017
46
Temporary Biventricular Assist Device to Bridge a Patient With Cardiogenic Shock Due to AL Amyloidosis to Heart Transplantation. ( 29230849 )
2017
47
Moving Beyond SHOCK: New Paradigms in the Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock. ( 28024554 )
2017
48
De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock. ( 28949061 )
2017
49
Reverse Takotsubo Cardiomyopathy and Cardiogenic Shock Associated With Methamphetamine Consumption. ( 28916123 )
2017
50
Early Initiation of Impella in Acute Myocardial Infarction Complicated byA Cardiogenic Shock Improves Survival: A Meta-Analysis. ( 28882288 )
2017

Variations for Cardiogenic Shock

Expression for Cardiogenic Shock

Search GEO for disease gene expression data for Cardiogenic Shock.

Pathways for Cardiogenic Shock

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.47 CRP IL6 PLAT
2
Show member pathways
11.19 CRP IL6
3 10.84 IL6 PLAT
4 9.9 CRP IL6

GO Terms for Cardiogenic Shock

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 acute-phase response GO:0006953 9.16 CRP IL6
2 platelet-derived growth factor receptor signaling pathway GO:0048008 8.96 PIK3C2A PLAT
3 negative regulation of lipid storage GO:0010888 8.62 CRP IL6

Sources for Cardiogenic Shock

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....